We are taking a win, closing our LLY position and minimizing risk just a few days before it reports second-quarter earnings.
Adults with type 2 diabetes treated with Tresiba ® (insulin degludec injection) had a significant reduction in HbA 1c and a 30 per cent lower rate of hypoglycemic episodes compared with those treated with Toujeo ® (insulin glargine U300) after starting...
Insulin has been around since 1921. But there is no generic drug and four companies control the market. Now politicians, the AMA and patient groups are looking for lower prices.
Pharma firm's new diabetes drug showed positive test results.
The Danish company's shares are enjoying their best day since May 2.
Senior vice president Enrique Conterno says the Type-2 diabetes treatment is part of the fast-growing glucagon-like peptide-1 receptor agonists.
We are picking up LLY shares into weakness, below our basis in the process.
While Donald Trump's tweets can shake up pharmaceutical stocks, history suggests that investors have little to fear from the president's drug pricing rhetoric.
BMO Capital Markets analyst Alex Arfaei says the fourth-quarter results show how dependent the drugmaker is on major diabetes assets 'and doesn't alleviate our concerns.'
A week after unveiling an $11.6-billion deal for Bioverativ, Sanofi said it was spending another $4.8 billion to acquire Belgian biotech firm Ablynx.
U.S. stock futures trade lower, Donald Trump's national security advisers look at building a 5G network, and France's Sanofi buys Belgian biotech Ablynx.
